Also, Apple killed yet another perfectly good product while panicking about the holiday season.

MINYANVILLE ORIGINAL Here are some highlights from this week in Minyanville’s coverage of the worlds of finance, politics, and more, just in case you missed them.

Why You Should Sell Apple Now By ChartLabPro.com What a difference a day makes. Today [Novemver 8], our Apple (NASDAQ:AAPL) ChartLabPro.com rating is a Strong Sell (1) on our 1-5 scale. This is an indication you should sell Apple now. This does not mean to short the stock. For readers who have been following us, you should have sold this name at $691 when it hit an approaching overbought level.

Is Foxconn Coming to the United States?Foxconn (TPE:2354) may be opening factories in the US. The Taiwan-based company, also known as the parent company Hon Hai Precision (TPE:2317), has been in the news recently for its reports on the difficulty of producing Apple products, such as the iPhone 5.

According to a DigiTimes report (via AppleInsider), Foxconn is evaluating cities such as Detroit, Michigan, and Los Angeles, California, as possible locations for the factories.

Warning: The Stock Market Panic Button Is About to Be PushedIn October, we published two articles suggesting that there might be a stock market panic in October (see hereand here). We were early. Whether the delay in the potential market panic was due to organic reasons, such as the excitement leading up to the November election, or some other factor is beyond the scope of this article. What we do know is that the day after the election the stock market had its worst day since November, 2011.

Google Has Been Blocked in ChinaJust as China, the world’s second largest economy, prepares itself for a congressional leadership transition, Web censorship sites are reporting that Google (NASDAQ:GOOG) has been blocked in certain parts of the country. According to an article by the Washington Post, Google and many of its subdomains have been blocked by a “DNS poison.” When attempting to access Google, Chinese users are now led to a vacant IP address, making it impossible for them to retrieve search results, access gmail, or check analytics.

Death by Apple: Five Products Killed in the Name of ProgressThis holiday season comes at a critical time for Apple. With the release of the iPad Mini and the rise of rival tablets like the Google Nexus 7, the Microsoft (NASDAQ:MSFT) Surface RT, and the huge number of e-readers that also compete in the tablet market, Apple is running into some stiff competition for holiday sales. But the company’s announcement of the iPad 4 only seven months since the last one seems to indicate that Apple is running scared, following the market that it usually prefers to lead. The announcement also continues a habit of Apple’s: a tendency to kill some of its own products.

With Xeljanz, Pfizer is believed to have a potential blockbuster -- a drug that potentially generates a few billion dollars a year in revenue, according to Wall Street analysts. Speculation by analysts also focuses on how much market share Pfizer can take from existing injected rheumatoid arthritis drugs, including Amgen’s (NASDAQ:AMGN) Enbrel, Johnson & Johnson’s (NYSE:JNJ) Remicade and the big gorilla, Abbott Laboratories’ (NYSE:ABT) Humira.

So what does this mean for the market? Well, Obama staying in office suggests no radical changes in the guard, which means the market can likely count on QE-Infinity, and the generally inflationary policies of the past few years, to continue. Barring a massive external deflationary event, this would seem to be bullish for equities over the longer-term.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.